Eli Lilly and Company

The University of Western Ontario

London Health Sciences Centre Research Inc.

Robarts Research Institute

Arthur Brown

Gregory A Dekaban

Kristine Kay Kikly

Ravi S Menon

Lisa Fischer

Timothy Doherty

Robert Bartha

Jeffrey Holmes

Tanya Charyk Stewart

J Kevin Shoemaker

Mark Daley

Charles A Rupar

Paul Gris

Douglas Dale Fraser

Lynne Weaver

Allan Barrett

Greg A Dekaban

Ravi Menon

Jeff Holmes

Tony Rupar

Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Anti-CD11D antibodies and uses thereof

A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and/or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion, stretch or partial cord transection), non-TBI brain injury and/or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b) using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.

Metabolomics profiling of central nervous system injury

A method of treating a pathophysiological condition caused by the production of growth-inhibiting proteoglycans is provided. It is based on the finding that down-regulation of SOX9 results in decreased production of growth-inhibiting factors such as proteoglycans, and increased production of growth-promoting factors such as a laminin and fibronectin. The method of the present invention comprises the inhibition of SOX9 expression and function with an inhibitor such as an antisense oligonucleotide or a siRNA.

Inhibition of SOX9 function in the treatment of proteoglycan-associated pathophysiological conditions

Growing community of inventors

London, Canada

Arthur Brown